Thyrocare Technologies Ltd

Q4 FY25Healthcare Services

Thyrocare Technologies Q4 FY25 earnings call: Revenue & Margins

Q4 FY25 earnings call: what management guided on revenue, margins and order book.

Price₹566

Market cap₹9.5K Cr

P/E52.8

Updated23 Aug 2026

Read4 min read

The short version

Mid-teens revenue growth expected for FY '26, with cautious optimism due to a high current base and industry growth of 10-11%. Revenue growth guidance for FY '26 is mid-teens percentage, reflecting cautious optimism due to a high base and competitive pressure.

From Thyrocare Technologies Ltd's Q4 FY25 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

Mid-teens revenue growth expected for FY '26, with cautious optimism due to a high current base and industry growth of 10-11%.
Volume growth anticipated around 14%, aligned closely with revenue growth due to tiered pricing structure, with no material price increases expected.
Franchisee network set to expand with plans to add 1,500 to 2,000 new franchise partners annually, supporting growth over next 3-5 years.
Partnership business growing strongly, including health tech and corporate/insurance segments, aiding volume and revenue expansion.
Continued focus on specialized test menu expansion, including allergy and genomics, poised to drive higher realization and growth.

2 more points management made on revenue & sales performance

Profitability & Margins

Revenue growth guidance for FY '26 is mid-teens percentage, reflecting cautious optimism due to a high base and competitive pressure.
Volume growth is expected around 14%, with revenue growth around 20% for recent years; for FY '26, mid-teen revenue growth is targeted.
EBITDA margin target for FY '26 is around 31% normalized, similar to FY '25 levels.
Operating leverage benefits are expected to sustain profitability, with investments continuing in specialized tests and new labs.
Smaller, consistent acquisitions (in the range of INR15-20 crores) will be selective and not materially impact earnings.
Franchisee addition is robust, targeting 1,500-2,000 new franchise partners annually for the next 3-5 years, supporting volume growth.

2 more points management made on profitability & margins

See what Thyrocare Technologies Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

For FY '25, capex was roughly INR 40-50 crores annually.
The company has sufficient cash flow to manage capex and acquisitions without stress.
No large amount has been set aside for acquisitions in FY '26; expected deployment around INR 15-20 crores focused on weaker geographies (Gujarat, Rajasthan, Northeast).
The company pursues a “string of pearls” acquisition strategy—small, focused acquisitions rather than large deals, due to management bandwidth considerations.
Capital investment in Nueclear centers is not planned currently, as a new center setup costs around INR 10 crores; focus remains on maintaining and optimizing existing centers.

2 more points management made on capital expenditure plans

Top-ranked in Healthcare Services

Ranked on what management guided this quarter

5x potential

1Health X Platform₹919 Cr

Rev 1Mar 1

2Chandan Healthca₹590 Cr

Rev 1Mar 3

3₹66.2K Cr

Rev 2Mar 1

4₹1.8K Cr

Rev 2Mar 2

5₹649 Cr

Rev 2Mar 2

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

No significant new fundraising through debt or equity is planned currently.
The company is a zero-debt entity with strong operating cash flow generation (INR191 crores in FY '25).
Annual capex is relatively low (INR40-50 crores), easily funded by internal cash flows.
The company maintains around INR80+ crores in cash reserves for contingencies and future investments.
Acquisitions are expected to be small (around INR15-20 crores for FY '25) in focused geographies; these will be funded through cash flows.

2 more points management made on fundraising & capital structure

See what Thyrocare Technologies Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The transcript does not explicitly mention the company's current or expected orderbook or pending orders. However, relevant insights related to growth and partnerships include: - Thyrocare is at a run rate of nearly INR 60 lakhs per quarter in partnership business, expecting ~100% growth next quarter. - Currently working with about 150 partners; cautious in adding new partners but steadily growing wallet share. - Franchise network growing robustly, with 1,500 to 2,000 new franchisees targeted annually.

2 more points management made on order book & pipeline

Thyrocare Technologies Ltd — Quarterly revenue & net profit

Revenue Net profit

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹224 Cr, net profit ₹49 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

What Thyrocare Technologies Ltd's management said in earlier quarters

Others in Healthcare Services this season

3B Blackbio DX Ltd (Q4 FY25)
UK subsidiary (TRUPCR Europe Limited) revenue FY 2024-25: GBP 1,287,580, a 94% increase over FY 2023-24 GBP 664,059. Key concall takeaways from 3B Blackbio DX…
Apollo Hospitals Enterprise Ltd (Q4 FY25)
. Key concall takeaways from Apollo Hospitals Enterprise Ltd's Q4 FY25 earnings call — and how it ranks against sector peers.
Shalby (Q4 FY25)
Implant business is in high-growth mode: 4x growth in Indonesia, 35-40% growth in U.S., and 2.5x growth in India reported last year. Key concall takeaways from…
Suraksha Diagno. (Q4 FY25)
Volume of tests conducted has been growing at around 10% year-on-year between FY '24 and FY '25. Key concall takeaways from Suraksha Diagnostic Ltd's Q4 FY25…

Compare:vs Apollo Hospitals Enterprise Ltd vs Max Healthcare vs Manipal Health

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Thyrocare Technologies Ltd Q4 FY25 results?

What is Thyrocare Technologies Ltd share price analysis?

Thyrocare Technologies Ltd currently shows a neutral. The stock trades at a P/E of 52.8 with a market cap of ₹9,550 Cr. Investors should review the full earnings analysis for detailed insights.

Is Thyrocare Technologies Ltd planning capital expenditure?

For FY '25, capex was roughly INR 40-50 crores annually.

Keep Thyrocare Technologies Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.